Education
About Us
Working with TipRanks
Follow Us
BiomX (PHGE)
:PHGE
PHGE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.34 - $1.19
Previous CloseN/A
Volume30.96K
Average Volume (3M)8.42M
Market Cap
$13.72M
Enterprise Value$27.08M
Total Cash (Recent Filing)$14.05M
Total Debt (Recent Filing)$9.38M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Nov 13, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding26,533,888
10 Day Avg. Volume323,165
30 Day Avg. Volume8,423,606
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.97
Enterprise Value/Revenue-322.44
Enterprise Value/Gross Profit-16.09
Enterprise Value/Ebitda-1.93
Forecast
1Y Price Target
$15.00Price Target Upside2784.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessBiomX recently announced positive topline results from the Phase 2 trial of BX211 for diabetic foot osteomyelitis.
Regulatory ApprovalThe company plans to meet with the FDA to discuss data collected on real-world evidence in CF patients, which could potentially streamline an approval pathway.
Bears Say
Clinical HoldA clinical hold was placed on the Phase 2 CF trial due to nebulizer safety concerns, but not related to BX004 as a clinical or product candidate.
Investor SentimentInvestor sentiment was negative, which is likely due to the p-values for the key endpoints.
BiomX News
PHGE FAQ
What was BiomX’s price range in the past 12 months?
BiomX lowest stock price was $0.34 and its highest was $1.19 in the past 12 months.
What is BiomX’s market cap?
BiomX’s market cap is $13.72M.
When is BiomX’s upcoming earnings report date?
BiomX’s upcoming earnings report date is Nov 13, 2025 which is in 66 days.
How were BiomX’s earnings last quarter?
BiomX released its earnings results on Aug 13, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.26 by $0.07.
Is BiomX overvalued?
According to Wall Street analysts BiomX’s price is currently Undervalued.
Does BiomX pay dividends?
BiomX does not currently pay dividends.
What is BiomX’s EPS estimate?
BiomX’s EPS estimate is -0.3.
How many shares outstanding does BiomX have?
BiomX has 26,533,888 shares outstanding.
What happened to BiomX’s price movement after its last earnings report?
BiomX reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.26. Following the earnings report the stock price went down -10.714%.
Which hedge fund is a major shareholder of BiomX?
Currently, no hedge funds are holding shares in PHGE
Company Description
BiomX
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
PHGE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
BiomX demonstrated significant progress in its clinical pipeline, particularly with the initiation of the BX004 Phase IIb trial and positive validation from published studies. However, financial challenges were evident with a decrease in cash balance and a reported net loss, offset by cost reductions. The sentiment reflects a balanced outlook with strong clinical momentum but financial caution.View all PHGE earnings summariesPHGE Stock 12 Month Forecast
Average Price Target
$15.00
▲(2784.62% Upside)
Technical Analysis
Curis
―
Cellectar Biosciences
―
ABVC BioPharma
―
Bolt Biotherapeutics
―
SAB Biotherapeutics
―
Ownership Overview
10.57% Insiders
31.95% Other Institutional Investors
57.48% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---